Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Artis Truett

Dermatology Owensboro, KY Medical Doctor

NPI 1215042429 CMS profile 236161

2821 New Hartford Rd, Owensboro, KY 42303

Open in the dashboard

General payments

$2,049

119 records reported · program years 2019–2025

Research payments

$10,797

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,393,048 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Artis Truett of Owensboro, KY is reported in the CMS Open Payments database as having received $2,049 across 119 general payments and $10,797 in research payments paid to them. Separately, studies naming them as principal investigator received $1,393,048 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $519 25
2024 General $373 24
2023 General $711 41
2022 General $151 10
2022 Research $425 1
2021 General $219 14
2020 General $48 3
2020 Research $3,891 2
2019 General $28 2
2019 Research $6,481 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Artis Truett
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Artis Truett were reported at $519. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Artis Truett Dermatology median Middle half National median
2019 $28 $454 $129–$1,240 $163
2020 $48 $235 $81–$756 $114
2021 $219 $377 $108–$1,108 $132
2022 $151 $514 $143–$1,391 $149
2023 $711 $607 $159–$1,674 $160
2024 $373 $751 $204–$1,903 $164
2025 $519 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $392 20 payments
  2. AbbVie, Inc. $375 27 payments
  3. Organogenesis Inc. $238 7 payments
  4. Novartis Pharmaceuticals Corporation $184 10 payments
  5. Regeneron Healthcare Solutions, Inc. $144 10 payments
  6. E.R. Squibb & Sons, L.L.C. $140 10 payments
  7. Sun Pharmaceutical Industries Inc. $114 5 payments
  8. Amgen Inc. $91 6 payments
  9. Genzyme Corporation $60 4 payments
  10. LEO Pharma Inc. $50 3 payments
  11. Other $262 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,866 117 payments
  2. Education $183 2 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $327 15 payments
  2. SKYRIZI $180 14 payments
  3. RINVOQ $150 10 payments
  4. SOTYKTU $127 9 payments
  5. NOVACHOR $106 1 payment
  6. COSENTYX $105 6 payments
  7. Otezla $91 6 payments
  8. DUPIXENT $68 5 payments
  9. SIMPONI ARIA $65 5 payments
  10. STELARA $65 5 payments
  11. Other $1,032 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $10,797 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

842

Median for Dermatology: 534

Drug cost

$481,983

Median for Dermatology: $67,151

Branded share of claims

16.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 11 $162,420
Otezla Apremilast Brand 22 $106,939
Humira Pen Adalimumab Brand 15 $106,539
Taltz Autoinjector Ixekizumab Brand 13 $88,462
Fluorouracil Generic 60 $3,959
Clobetasol Propionate Generic 77 $3,118
Ketoconazole Generic 83 $1,504
Dapsone Generic 20 $1,218
Fluticasone Propionate Generic 60 $1,163
Doxycycline Hyclate Generic 56 $1,087

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 148 billing codes

Paid by Medicare

$1,712,448

Of which drugs: $319,562

Medicare patients

1,463

Average age 77

Services billed

16,955

637 women, 826 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Ischemic heart disease 32%
Diabetes 28%
Chronic kidney disease 23%
Atrial fibrillation 20%
Heart failure 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Membrane graft or membrane wrap, per square centimeter Q4205 Office 11 248 $238,453
Epieffect, per square centimeter Q4278 Office 11 144 $40,456
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 31 91 $58
Injection, fluorouracil, 500 mg J9190 Office 11 13 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
  • Amgen Inc. $60
$60 22 —
RINVOQ
  • AbbVie, Inc. $56
$56 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $55
$55 — —
DUPIXENT
  • GENZYME CORPORATION $27
  • Regeneron Healthcare Solutions, Inc. $17
$44 — —
SPEVIGO
  • Boehringer Ingelheim Pharmaceuticals, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record